NCT Number: NCT01139983
DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying DNA biomarkers in samples from patients with osteosarcoma and healthy volunteers.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
About this study
OBJECTIVES:
- To determine whether common copy-number alterations (CNAs) at chr7p14.1 arise de novo in osteosarcoma (OS) tumor DNA or whether they represent progression of constitutional copy-number variations (CNVs).
- To determine the association between constitutional CNVs at chr7p14.1 and susceptibility to OS.
- To determine how CNVs translate into CNAs in tumor DNA samples from patients with OS.
OUTLINE: RNA and DNA samples from banked blood and paired tumor tissue, plus samples from healthy controls, are analyzed for common copy-number alterations and constitutional copy-number variations (CNVs) at chr7p14.1 by microarray, q-PCR, RT-PCR, and FISH. Osteosarcoma predisposing CNVs results are then compared among cases versus healthy controls.
Clinical information associated with each osteosarcoma sample (i.e., gender, age of diagnosis, tumor site, tumor type and grade, presence of metastases at time of diagnosis, response to chemotherapy, event-free survival, and overall survival) is also collected, if available.
PROJECTED ACCRUAL: A total of 243 samples from patients with osteosarcoma and 80 samples from healthy controls will be accrued to this study.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Meets 1 of the following criteria:
- Diagnosis of osteosarcoma (OS) and meets 1 of the following criteria:
- Original 153 OS samples, including paired germline and tumor DNA
- Additional samples from 90 patients with OS:
- Blood samples
- Germline DNA
- Paired tumor biopsy tissue (not from resection) obtained before systemic chemotherapy
- Healthy controls, age- and gender-matched
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Treatment and study plan
RNA analysis
Geneticfluorescence in situ hybridization
Geneticmicroarray analysis
Geneticpolymerase chain reaction
Geneticreverse transcriptase-polymerase chain reaction
Geneticlaboratory biomarker analysis
OtherPrimary outcomes
-
Role of copy-number alterations (CNAs) in the etiology of osteosarcoma
-
Association between copy-number variations (CNVs) at chr7p14.1 and susceptibility to osteosarcoma
-
Relationship between CNVs and tumor CNAs in osteosarcoma
Sponsors and collaborators
Lead sponsor
Children's Oncology Group
Network
Collaborators
- National Cancer Institute (NCI)
Registry information
Official study title
Search for Novel Genes in Osteosarcoma Revealed by Analysis of Tumour Copy-Number Alterations and Constitutional Copy-Number Variations
Important dates
- Study start
- 2010
- Primary completion
- 2016
- First posted
- Jun 9, 2010
- Registry last updated
- May 18, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
NCT02406781
Leiomyosarcoma, Neoplasms
Bordeaux, France
View Trial DetailsMachine Learning Applied to EHRs Data of Patients With Sarcoma
NCT07215728
Ewing Sarcoma, Neoplasms
View Trial DetailsThe Registry of Oncology Outcomes Associated With Testing and Treatment
NCT04028479
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Idaho Falls, Idaho, United States
View Trial DetailsA Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
NCT02107963
Melanoma, Neoplasms
Bethesda, Maryland, United States
View Trial Details